rs6050 — FGA Thr312Ala

Missense variant in the fibrinogen alpha chain (FGA) that substitutes alanine for threonine at position 312, altering the alphaC domain targeted by factor XIIIa cross-linking and producing denser, lysis-resistant fibrin clots associated with elevated venous thromboembolism and pulmonary embolism risk

See your personal result for FGA

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

FGA Thr312Ala — When Fibrin Fights Dissolution

Fibrinogen11 Fibrinogen
A 340 kDa plasma protein synthesized in the liver that circulates at 2–4 g/L. Thrombin cleaves fibrinogen to produce fibrin monomers that polymerize into the mesh scaffold of a blood clot is the final common substrate of coagulation. The FGA gene encodes the fibrinogen alpha chain, one of three polypeptide chains that assemble into the hexameric fibrinogen molecule. The Thr312Ala variant (rs6050) substitutes alanine for threonine at position 312 of the alpha chain — precisely within the alphaC domain, a region critical for lateral fibrin aggregation and for the cross-linking reactions that give a mature clot its tensile strength. Whether you carry this substitution shapes not just whether a clot forms, but how easily it can be dissolved once formed — a distinction with specific implications for pulmonary embolism risk.

The Mechanism

When thrombin cleaves fibrinogen, the resulting fibrin monomers polymerize end-to-end into protofibrils. These protofibrils then laterally aggregate — a process partly mediated by the alphaC domain22 alphaC domain
The C-terminal portion of the fibrinogen alpha chain, spanning residues ~220–610, that mediates lateral protofibril aggregation and Factor XIIIa cross-linking sites including the αC-αC connector region — before becoming covalently stabilized by Factor XIIIa33 Factor XIIIa
Factor XIII is a transglutaminase activated by thrombin; it covalently cross-links adjacent fibrin alpha and gamma chains, converting the gel into a mechanically resistant clot.

Standeven et al. demonstrated44 Standeven et al. demonstrated
Standeven KF et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation, 2003 that the Ala312 variant falls within the region of the alpha chain targeted by Factor XIIIa for alpha-alpha cross-linking. The substitution alters the geometry of this domain, enhancing the efficiency of Factor XIIIa-mediated cross-linking between adjacent alpha chains. The consequence is a fibrin network with a more compact architecture: denser fiber packing, reduced pore size, and — critically — greater resistance to fibrinolysis by plasmin. Clots formed from Ala312 fibrinogen are structurally stiffer and dissolve more slowly.

This mechanism explains the selectivity of the risk: pulmonary embolism, not deep vein thrombosis is the predominant association. A denser, plasmin-resistant clot is more likely to embolize intact before local thrombolysis can fragment it. DVT formation is determined more by flow conditions and early thrombin generation; the lysis-resistant clot phenotype becomes clinically relevant downstream, when the thrombus must be dissolved or risks breaking off.

The Evidence

The original clinical association was established by Carter et al. 200055 Carter et al. 2000
Carter AM et al. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood, 2000 in a study of 99 pulmonary embolism patients, 122 DVT patients, and 254 healthy controls. The Ala312 genotype frequency was 15% in PE patients versus 6% in controls (P=.02), while DVT patients showed no significant difference from controls. A significant genotype-by-genotype interaction was also found between Thr312Ala and the Factor XIII Val34Leu variant (rs5985, P=.01), consistent with their shared biology at the Factor XIIIa cross-linking interface.

An earlier landmark finding came from Carter et al. 199966 Carter et al. 1999
Carter AM et al. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation, 1999 in 519 acute ischemic stroke patients. Among the 101 patients with atrial fibrillation — a condition associated with intra-atrial thrombus formation — survival differed strikingly by genotype: TT carriers had 42% survival, TA heterozygotes 18%, and AA homozygotes 0%. The authors proposed that Ala312-containing fibrinogen makes atrial thrombi more lysis-resistant and more susceptible to embolization, providing a coherent structural explanation for why clot structure — not just clot presence — determines embolic outcome.

A 2025 meta-analysis by Cheng et al.77 meta-analysis by Cheng et al.
Cheng H et al. Association of Fibrinogen Aα Thr312Ala polymorphism with VTE and chronic thromboembolic pulmonary hypertension: a meta-analysis. Clin Appl Thromb Hemost, 2025 synthesized 11 studies covering 3,856 individuals with VTE events and 761 with chronic thromboembolic pulmonary hypertension88 chronic thromboembolic pulmonary hypertension
CTEPH arises when pulmonary emboli fail to fully resolve, leaving organized clot that progressively obstructs pulmonary arteries — the structural counterpart of the fibrinolysis-resistant clot phenotype that Ala312 fibrinogen produces. The Ala312 allele was consistently associated with elevated VTE and CTEPH risk across all genetic models in Caucasian and Asian populations. The CTEPH association is particularly striking: CTEPH is the long-term consequence of recurrent or incompletely lysed pulmonary emboli, exactly the pathological endpoint predicted by lysis-resistant fibrin clot structure.

The variant is not significantly associated with coronary artery disease in cohort data, consistent with its mechanism being fibrinolysis resistance rather than initial atherothrombotic plaque rupture.

Practical Implications

Carrying the Ala312 allele does not cause thrombosis on its own — the background risk requires permissive conditions: prolonged immobility, surgery, oral contraceptives, pregnancy, cancer, or a second thrombophilic variant such as Factor V Leiden (rs6025) or prothrombin G20210A (rs1799963). What this variant does is shift the structural phenotype of fibrin clots toward greater lysis resistance, increasing the probability that a thrombus that forms will embolize or persist. Awareness of this genotype should heighten attention to VTE prevention during high-risk periods and prompt early investigation when symptoms of PE occur.

Women using combined oral contraceptives face a substantially amplified risk if they also carry Ala312: estrogens already raise fibrinogen levels and shift clot structure toward a prothrombotic phenotype; Ala312 compounds this by making the resulting clot harder to dissolve.

Interactions

Factor XIII Val34Leu (rs5985): The Carter 2000 paper identified a significant interaction (P=.01) between Thr312Ala and Factor XIII Val34Leu. These two variants affect opposite sides of the same biochemical event — Ala312 in the fibrinogen alpha chain substrate, and Leu34 in the Factor XIIIa enzyme — and their combined effect on clot structure is not simply additive. Leu34 increases Factor XIIIa activation rate; Ala312 alters the cross-linking geometry. Co-carriage may produce a distinctly abnormal clot phenotype.

FGB -455G>A (rs1800790): The Klajmon 2022 study (PMID 34783023) found that FGB rs1800790 A allele (reduced fibrinogen beta chain expression) affects fibrin clot permeability and lysis time in acute PE, while FGA rs6050 alone did not reach significance in that dataset. This suggests the two fibrinogen chain variants have partially independent and potentially interacting effects on clot structure.

Factor V Leiden (rs6025) and Prothrombin G20210A (rs1799963): These classic inherited thrombophilias act upstream (at the coagulation protease level) while Ala312 acts downstream (at the fibrin scaffold level). Co-inheritance of Ala312 with Factor V Leiden creates both increased thrombin generation and a structurally resistant clot — a compounded thrombophilic state warranting lower threshold for anticoagulation after a first VTE event.

Genotype Interpretations

What each possible genotype means for this variant.

TT Common Genotype Normal

Both copies carry the common Thr312 allele — normal fibrin clot structure

You carry two copies of the T allele (Thr312), the most common form of the fibrinogen alpha chain globally. About 54% of people share this genotype. Your FGA alpha chain has the standard threonine at position 312, which means Factor XIIIa cross-links your fibrin at baseline efficiency. Your clots have normal fiber architecture and normal susceptibility to fibrinolysis by plasmin. This result does not eliminate VTE risk — which depends on many genetic and environmental factors — but it means this particular fibrin-structure mechanism does not contribute to your risk.

CT Heterozygous Ala312 Intermediate

One copy of the Ala312 allele — moderately altered fibrin clot architecture and modestly elevated pulmonary embolism risk

The functional consequence of the Ala312 variant was characterized in vitro by Standeven et al. (2003, Circulation, PMID 12707238): the substitution of threonine by alanine at position 312 falls within the alphaC-connector region of the FGA alpha chain. This region participates in both lateral protofibril aggregation and is a substrate for Factor XIIIa transglutaminase cross-linking. The Ala312 geometry enhances Factor XIIIa cross-linking efficiency between adjacent alpha chains, producing clots with denser packing and reduced pore size. These structural changes translate into clots that are mechanically stiffer and more resistant to plasmin-mediated fibrinolysis — the body's primary mechanism for resolving intravascular thrombi.

The clinical implication is primarily for pulmonary embolism risk rather than DVT per se: clots that form under prothrombotic conditions are less likely to be dissolved locally before a fragment detaches and embolizes to the pulmonary vasculature. The 2025 meta-analysis by Cheng et al. (PMID 39838925) confirmed the association extends to chronic thromboembolic pulmonary hypertension (CTEPH), a condition where recurrent, incompletely dissolved pulmonary emboli progressively obstruct pulmonary arteries — the precise long-term sequela of fibrinolysis-resistant clots.

Heterozygous carriers produce a mixture of normal Thr312 and variant Ala312 fibrinogen molecules. The degree of structural shift depends on relative expression levels, local thrombin concentrations, and concurrent Factor XIII Val34Leu genotype (rs5985), which modulates the kinetics of cross-linking activity at the same biochemical interface.

CC Homozygous Ala312 High Risk

Both copies carry the Ala312 allele — substantially altered fibrin structure and elevated pulmonary embolism risk

Homozygous Ala312/Ala312 carriers produce fibrinogen in which all alpha chains carry the variant residue. In vitro, Ala312 fibrinogen shows enhanced Factor XIIIa cross-linking kinetics at the alphaC domain — the region responsible for alpha-alpha covalent bonds that give the final clot mesh much of its mechanical resistance. The result is a fibrin network with denser fiber packing, reduced pore size (limiting plasminogen access to fibrin strands), and prolonged clot lysis time under plasmin challenge.

The clinical significance manifests primarily as elevated pulmonary embolism risk rather than DVT: DVT formation is primarily determined by stasis, vascular injury, and hypercoagulability (Virchow's triad), while the subsequent risk of PE is determined by whether local plasmin can dissolve the thrombus before it embolizes. Ala312 fibrinogen tips this balance toward embolization.

The association extends to chronic thromboembolic pulmonary hypertension (CTEPH) — a condition where repeated or massive pulmonary emboli fail to fully resolve and become organized fibrous obstructions. CTEPH is the mechanistic endpoint of fibrinolysis-resistant clots in the pulmonary vasculature, and the Cheng 2025 meta-analysis confirmed CTEPH association under all genetic models except the recessive model, suggesting the allele contributes even in heterozygotes.

Interaction with Factor XIII Val34Leu (rs5985) is documented: these two variants affect the enzyme (FXIII) and substrate (fibrinogen alpha chain) in the same cross-linking reaction, and co-carriage may produce a clot phenotype that differs non-additively from either alone.